- Home
- GWH vs ATRA Comparison
GWH vs ATRA Comparison
Compare GWH & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- ATRA
- Stock Information
- Founded
- GWH 2011
- ATRA 2012
- Country
- GWH United States
- ATRA United States
- Employees
- GWH N/A
- ATRA N/A
- Industry
- GWH Industrial Machinery/Components
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GWH Miscellaneous
- ATRA Health Care
- Exchange
- GWH Nasdaq
- ATRA Nasdaq
- Market Cap
- GWH 39.6M
- ATRA 35.2M
- IPO Year
- GWH N/A
- ATRA 2014
- Fundamental
- Price
- GWH $2.59
- ATRA $6.13
- Analyst Decision
- GWH Hold
- ATRA Buy
- Analyst Count
- GWH 5
- ATRA 6
- Target Price
- GWH $3.35
- ATRA $25.70
- AVG Volume (30 Days)
- GWH 49.5K
- ATRA 52.1K
- Earning Date
- GWH 03-31-2025
- ATRA 05-08-2025
- Dividend Yield
- GWH N/A
- ATRA N/A
- EPS Growth
- GWH N/A
- ATRA N/A
- EPS
- GWH N/A
- ATRA N/A
- Revenue
- GWH $6,295,000.00
- ATRA $128,940,000.00
- Revenue This Year
- GWH $23.79
- ATRA N/A
- Revenue Next Year
- GWH $331.34
- ATRA $43.69
- P/E Ratio
- GWH N/A
- ATRA N/A
- Revenue Growth
- GWH N/A
- ATRA 1404.02
- 52 Week Low
- GWH $2.51
- ATRA $5.40
- 52 Week High
- GWH $14.10
- ATRA $20.83
- Technical
- Relative Strength Index (RSI)
- GWH 30.06
- ATRA 38.50
- Support Level
- GWH $3.20
- ATRA $6.53
- Resistance Level
- GWH $3.55
- ATRA $6.90
- Average True Range (ATR)
- GWH 0.27
- ATRA 0.46
- MACD
- GWH 0.00
- ATRA -0.01
- Stochastic Oscillator
- GWH 6.85
- ATRA 22.63
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).